Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mivavotinib + nivolumab
- Development stage
- Discontinued
- Lead developer
- Takeda
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Mivavotinib + nivolumab is an investigational combination therapy consisting of mivavotinib (TAK-659/CB-659), a dual spleen tyrosine kinase (SYK) and FMS-like tyrosine kinase 3 (FLT3) inhibitor, and nivolumab, a programmed death 1 (PD-1) immune checkpoint inhibitor monoclonal antibody. Mivavotinib targets SYK and FLT3 to reduce immunosuppressive immune cell populations and suppress tumor growth. Nivolumab blocks PD-1 on T cells to enhance anti-tumor immune responses. The combination has been studied in advanced solid tumors including triple-negative breast cancer (TNBC), aiming to improve immunotherapy efficacy by modulating both tumor-intrinsic signaling pathways and the tumor microenvironment[1][2][5].
- Other names
- mivavotinib plus nivolumabTAK-659 plus nivolumabTAK659 plus nivolumabTAK 659 plus nivolumabCB-659 plus nivolumabCB659 plus nivolumabCB 659 plus nivolumab
02
Targets
FLT3 (Fms related receptor tyrosine kinase 3)PDCD1 (Programmed cell death protein 1 receptor)SYK (Spleen Tyrosine Kinase)
Beyond the preview
Go deeper on mivavotinib + nivolumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mivavotinib + nivolumab.